Close Menu

NEW YORK – Quest Diagnostics today reported a 5 percent year-over-year rise in revenues for the fourth quarter, beating the consensus expectation from Wall Street analysts.

Revenue for the three months ended Dec. 31, 2019 was $1.93 billion, up from $1.84 billion in the same quarter last year. The consensus Wall Street estimate was $1.92 billion.

Test volumes grew 4 percent during the quarter with revenue per test growing a little more than 1 percent.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.


This webinar will describe a rapid metagenomics assay under development for human pathogens, including the SARS-CoV-2 coronavirus.

Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.


This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.